Abstract

Calcitonin Gene-Related Peptide (CGRP) is a highly conserved 37-amino acid neuropeptide belonging to the calcitonin family, recognized for its profound and diverse physiological roles. While its pivotal involvement in migraine pathophysiology and its subsequent emergence as a primary therapeutic target have garnered significant attention, CGRP’s functions extend far beyond the confines of headache disorders. This comprehensive review aims to provide an exhaustive exploration of CGRP, delving into its historical discovery, the intricate molecular mechanisms governing its actions, and its multifaceted physiological contributions across various organ systems, including the cardiovascular, gastrointestinal, immune, respiratory, and musculoskeletal systems. Furthermore, it will meticulously detail the evolution of CGRP-targeted therapies, encompassing both monoclonal antibodies and small molecule antagonists, and critically examine the future directions, opportunities, and persistent challenges within this rapidly advancing field.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Calcitonin Gene-Related Peptide (CGRP), a highly conserved 37-amino acid neuropeptide, stands as a prominent member of the calcitonin family of peptides. This family also encompasses calcitonin, adrenomedullin (AM), amylin, and intermedin/adrenomedullin 2 (AM2) [1, 2]. Discovered in the early 1980s, CGRP has since become one of the most intensively studied neuropeptides due to its remarkably potent and pleiotropic biological activities [3]. Its widespread distribution throughout both the central and peripheral nervous systems underscores its fundamental role as a neurotransmitter and neuromodulator [4].

The human CGRP exists in two primary isoforms, alpha-CGRP (αCGRP) and beta-CGRP (βCGRP), which are products of distinct genes located on chromosome 11. While both isoforms are 37 amino acids long and share a high degree of sequence homology (differing by only three amino acids in humans), αCGRP is far more extensively studied and understood, particularly in the context of migraine [2, 5]. αCGRP is predominantly expressed in the nervous system, including sensory neurons of the dorsal root ganglia (DRG), trigeminal ganglion (TG), and various brain regions, as well as in the enteric nervous system and cardiovascular system. βCGRP, though less abundant, is also found in nervous tissues and exhibits similar, albeit sometimes quantitatively weaker, biological activities to αCGRP [2].

Initial research into CGRP quickly identified its potent vasodilatory properties, positioning it as a key player in circulatory regulation. However, its profound connection to nociception, particularly in the context of migraine, later propelled it to the forefront of neuroscience and pharmacology [3, 6]. Emerging research has consistently highlighted its intricate involvement in a diverse array of physiological processes beyond headache disorders, including but not limited to, cardiovascular homeostasis, gastrointestinal motility and secretion, immune and inflammatory responses, respiratory function, bone metabolism, and even neuroprotection [2, 7].

This review aims to provide a comprehensive and in-depth understanding of CGRP’s multifaceted roles. It will systematically explore the historical milestones that led to its discovery, meticulously dissect the molecular mechanisms through which it exerts its diverse actions, and elaborate on its widespread physiological implications. Crucially, it will then transition to the transformative impact of CGRP-targeted therapies, which have revolutionized the treatment landscape for migraine and continue to hold promise for other CGRP-mediated conditions. By synthesizing current knowledge, this review seeks to underscore the profound clinical relevance of CGRP and delineate future directions for research and therapeutic development.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Historical Context and Discovery of CGRP

The journey of CGRP from an enigmatic gene product to a well-understood neuropeptide with significant therapeutic implications is a testament to advancements in molecular biology and neuroscience. Its discovery in 1982 by Susan Amara, Ronald Rosenfeld, and Michael Evans, working in the laboratory of Robert Evans at the Salk Institute, marked a pivotal moment [8]. The breakthrough arose from their investigation into the calcitonin gene, which was known to produce the hormone calcitonin, primarily involved in calcium homeostasis. However, using then-novel recombinant DNA technology, they uncovered an unexpected phenomenon: alternative splicing of the primary RNA transcript of the calcitonin gene [8, 9].

Alternative splicing is a molecular process that allows a single gene to encode multiple protein products. In the case of the calcitonin gene, depending on the tissue, the primary transcript could be processed in two distinct ways. In the thyroid C-cells, it primarily produced messenger RNA (mRNA) for calcitonin. However, in neuronal tissues, particularly the brain and spinal cord, the same gene’s RNA was processed differently, leading to the expression of a novel peptide that was structurally related to, but functionally distinct from, calcitonin. This newly identified peptide was named Calcitonin Gene-Related Peptide, or CGRP, reflecting its genetic origin [8, 9, 10].

Initial characterization of CGRP revealed its significant presence in the central and peripheral nervous systems, particularly within sensory neurons. This anatomical distribution immediately suggested a role in neural signaling. Early pharmacological studies quickly identified CGRP as an exceptionally potent vasodilator, capable of inducing significant relaxation of various blood vessels, often more potently than other known vasodilators [11, 12]. This striking cardiovascular effect contrasted sharply with calcitonin’s primary role in bone and calcium metabolism, indicating that despite their shared genetic heritage, these peptides had diverged in their physiological functions.

The early 1980s also saw burgeoning research into the neurobiology of pain. Researchers began to investigate the role of various neuropeptides in nociceptive transmission. Given CGRP’s presence in primary afferent neurons – the sensory nerves responsible for transmitting pain signals from the periphery to the central nervous system – it was naturally hypothesized to play a role in pain [13]. Subsequent studies confirmed its release from sensory nerve terminals in response to noxious stimuli, leading to local inflammation and sensitization of pain receptors [14].

The link between CGRP and migraine pain specifically began to solidify in the late 1980s and 1990s. Groundbreaking studies, notably by Lars Edvinsson and Peter Goadsby, demonstrated elevated levels of CGRP in the jugular venous blood during migraine attacks, which subsequently normalized upon successful treatment with triptans, a class of migraine drugs known to constrict cranial blood vessels [15, 16]. This observation provided compelling evidence that CGRP was not merely a bystander but an active participant in migraine pathophysiology, specifically implicated in the neurogenic inflammation and vasodilation thought to drive the pain of a migraine attack. This paradigm shift in understanding migraine’s neurobiology laid the groundwork for the development of CGRP-targeted therapies, representing a significant advancement from symptomatic treatments to mechanism-based preventive and acute interventions [17, 18]. The journey from gene discovery to targeted therapy highlights a successful translational research pathway that has profoundly impacted patient care.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Molecular Mechanisms of CGRP Action

CGRP exerts its diverse physiological effects by interacting with specific high-affinity receptors located on the surface of target cells. Unlike many other peptide receptors, the functional CGRP receptor is not a single protein but a sophisticated heterotrimeric complex, crucial for both ligand binding specificity and intracellular signal transduction [19, 20].

3.1 CGRP Receptor Complex

The functional CGRP receptor is a G protein-coupled receptor (GPCR) complex composed of three essential components:

1. Calcitonin Receptor-Like Receptor (CALCRL): This is the core seven-transmembrane GPCR component [21]. However, CALCRL is inherently promiscuous; by itself, it cannot specifically bind CGRP with high affinity nor can it effectively signal. Its ligand specificity is conferred by accessory proteins.

2. Receptor Activity-Modifying Proteins (RAMPs): These are single-transmembrane proteins that play a critical role in receptor trafficking, ligand binding, and signaling specificity. There are three known RAMPs (RAMP1, RAMP2, RAMP3), each pairing with CALCRL to form distinct functional receptors:

   • CALCRL + RAMP1: This combination forms the canonical, high-affinity CGRP receptor. RAMP1 is indispensable for the surface expression and CGRP-binding specificity of CALCRL [19, 22].
   • CALCRL + RAMP2: This complex constitutes the adrenomedullin 1 (AM1) receptor, primarily binding adrenomedullin.
   • CALCRL + RAMP3: This complex forms the adrenomedullin 2 (AM2) receptor, also primarily binding adrenomedullin, though it can bind CGRP with lower affinity [19].

3. Receptor Component Protein (RCP): While not directly involved in ligand binding, RCP is an intracellular protein that is essential for coupling the CALCRL-RAMP complex to downstream intracellular signaling pathways [23]. Without RCP, even if CGRP binds to the CALCRL-RAMP1 complex, effective signal transduction is significantly impaired or abolished. RCP facilitates the interaction between the receptor and G proteins, ensuring efficient signal propagation [23].

Therefore, the fully functional CGRP receptor, responsible for mediating the vast majority of CGRP’s known physiological effects, is precisely the complex of CALCRL, RAMP1, and RCP, strategically organized on the cell membrane [20].

3.2 Intracellular Signaling Pathways

Upon CGRP binding to its specific receptor complex (CALCRL-RAMP1-RCP), a cascade of intracellular signaling events is initiated. The CGRP receptor is predominantly coupled to Gs proteins (stimulatory G proteins) [24]. This coupling leads to the activation of adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) [24].

The resultant increase in intracellular cAMP levels is a primary second messenger response. Elevated cAMP then activates Protein Kinase A (PKA), a serine/threonine kinase [25]. PKA, in turn, phosphorylates a range of intracellular target proteins, leading to a variety of cellular responses depending on the cell type. In vascular smooth muscle cells, PKA activation leads to muscle relaxation and vasodilation through several mechanisms, including:

• Phosphorylation of myosin light chain kinase (MLCK): This reduces MLCK’s sensitivity to Ca2+, thereby inhibiting the phosphorylation of myosin light chain, which is crucial for muscle contraction [26].
• Activation of potassium channels (e.g., KATP channels): This leads to hyperpolarization of the cell membrane, making it less excitable and reducing calcium influx [27].
• Inhibition of Ca2+ channels: Reducing intracellular calcium concentrations [26].
• Increased sequestration of intracellular Ca2+: Enhancing the activity of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps [26].

While the Gs/cAMP/PKA pathway is the most prominent and well-characterized signaling route for CGRP, there is evidence suggesting that CGRP may also activate other pathways, albeit to a lesser extent or in specific cell types. These include the activation of the mitogen-activated protein kinase (MAPK) pathway (e.g., ERK1/2) and potentially Gq protein coupling, leading to phosphoinositide hydrolysis and increases in intracellular Ca2+, although these are less commonly observed for vasodilation [2]. The specificity of the receptor complex ensures that CGRP’s actions are tightly regulated and precisely targeted.

3.3 CGRP Release and Role in Migraine Pathophysiology

The understanding of CGRP’s molecular mechanisms is critically important for its role in migraine pathophysiology. The trigeminal nervous system (TNS) plays a central role in migraine. The cell bodies of trigeminal neurons are located in the trigeminal ganglion (TG), whose axons innervate the cranial vasculature, particularly the meningeal blood vessels [28]. These perivascular nerve fibers are rich in CGRP.

During a migraine attack, various triggers (e.g., stress, hormonal changes, certain foods, sensory stimuli like bright light or loud sounds) activate these trigeminal afferents. This neuronal activation leads to the release of CGRP from the peripheral terminals of trigeminal neurons, primarily into the perivascular space surrounding the meningeal arteries [29, 30].

Once released, CGRP interacts with its receptors on several cell types within the dura mater and its associated blood vessels:

• Vascular Smooth Muscle Cells: CGRP’s potent vasodilatory effect on cranial blood vessels, mediated via the Gs/cAMP pathway described above, contributes to the pulsating pain characteristic of migraine. This vasodilation increases blood flow and stretches the perivascular nerve endings, further activating nociceptors [31].
• Mast Cells: CGRP can induce mast cell degranulation, leading to the release of pro-inflammatory mediators such as histamine, serotonin, and proteases. These mediators contribute to a process known as neurogenic inflammation, characterized by plasma protein extravasation (leakage of fluid from blood vessels) and further sensitization of pain fibers [32].
• Schwann Cells: CGRP receptors are also found on Schwann cells surrounding trigeminal nerves. CGRP’s interaction here may contribute to neuroinflammation and neuronal excitability [33].
• Sensitization of Nociceptors: CGRP directly and indirectly sensitizes both peripheral and central nociceptive neurons. Peripherally, it lowers the activation threshold of trigeminal afferents, making them more responsive to painful stimuli (peripheral sensitization). Centrally, prolonged afferent input, partly mediated by CGRP released in the trigeminal nucleus caudalis (TNC) in the brainstem, leads to changes in the central pain pathways, resulting in central sensitization. This central sensitization can manifest as allodynia (pain from non-painful stimuli) and hyperalgesia (increased pain from painful stimuli), often experienced during migraine attacks [34, 35].

In essence, CGRP acts as a key effector molecule in the trigeminal pain pathway, bridging the gap between neuronal activation and the multifaceted symptoms of migraine. Its release initiates a cascade of events—vasodilation, neurogenic inflammation, and neuronal sensitization—that collectively contribute to the intense, debilitating pain and associated symptoms (like photophobia and phonophobia) experienced by migraineurs [36]. This detailed understanding of CGRP’s role has been instrumental in the rational design of targeted therapeutic strategies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Physiological Roles of CGRP Beyond Migraine

While migraine has brought CGRP into the spotlight, the neuropeptide’s physiological footprint is far-reaching, influencing numerous organ systems and fundamental biological processes. Its widespread distribution in both the central and peripheral nervous systems, coupled with the ubiquitous presence of its receptors on various cell types, underscores its broad neuromodulatory and effector functions.

4.1 Cardiovascular System

CGRP is arguably the most potent endogenous vasodilator identified to date [11, 12]. Its profound effects on the cardiovascular system are well-documented and extend beyond its role in cranial vasodilation during migraine.

• Vasodilation and Blood Pressure Regulation: CGRP induces relaxation of vascular smooth muscle cells across various vascular beds, including coronary, cerebral, renal, pulmonary, and cutaneous arteries [26]. This effect is mediated primarily through the Gs/cAMP/PKA pathway, leading to a decrease in intracellular calcium and subsequent smooth muscle relaxation. The potent vasodilatory action contributes to its role in blood pressure regulation. Exogenously administered CGRP can lead to a significant drop in systemic blood pressure, and endogenous CGRP likely plays a tonic role in maintaining vascular tone [37].
• Cardiac Effects: While primarily a vasodilator, CGRP also has direct and indirect effects on the heart. It can cause a positive chronotropic (increased heart rate) and inotropic (increased contractility) effect, although these are often secondary to its hypotensive actions leading to reflex sympathetic activation [38]. CGRP receptors are present in cardiac myocytes, and direct effects may include modulation of ion channels and calcium handling [38].
• Protective Roles: CGRP has demonstrated protective roles in various cardiovascular pathologies. For instance, in conditions like myocardial ischemia-reperfusion injury, CGRP release can improve blood flow and reduce infarct size [39]. It is also implicated in the adaptive responses to conditions like hypertension and heart failure, where its release may serve as a compensatory mechanism to counteract vasoconstriction and improve cardiac output [37]. Elevated CGRP levels are often observed in patients with heart failure, potentially reflecting a compensatory mechanism against increased cardiac workload [40].
• Pathological Implications: While generally viewed as protective in vascular health, dysregulation of CGRP signaling can contribute to disease states. For example, in sepsis and septic shock, massive CGRP release can lead to profound and uncontrolled vasodilation, contributing to the severe hypotension characteristic of these conditions [41]. Its role in endothelial dysfunction and atherosclerosis is complex and subject to ongoing research, with both protective and potentially detrimental aspects being explored [37].

4.2 Gastrointestinal System

CGRP is abundantly present in the enteric nervous system (ENS) and spinal afferent neurons innervating the gastrointestinal (GI) tract, where it acts as a crucial regulator of gut function [42].

• Motility Modulation: CGRP generally exerts inhibitory effects on GI motility. It has been shown to inhibit gastric emptying and slow intestinal transit [43]. This inhibitory action can occur via direct effects on smooth muscle cells or through modulation of ENS neurons. For example, CGRP released from extrinsic afferents can inhibit acetylcholine release from intrinsic motor neurons, thereby relaxing gut musculature [42]. This role suggests its involvement in conditions like irritable bowel syndrome (IBS), where motility dysregulation is common.
• Secretory Functions: CGRP can influence various secretory processes within the GI tract. It is a potent inhibitor of gastric acid secretion, potentially acting through both neural and direct effects on parietal cells [44]. It also modulates pancreatic exocrine and endocrine secretions, and intestinal fluid and electrolyte transport [42].
• Visceral Pain and Inflammation: CGRP plays a significant role in transmitting visceral nociception. Its release from sensory nerve endings in response to inflammation or irritation in the gut contributes to visceral hypersensitivity and pain [45]. In inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, CGRP levels can be altered, suggesting its involvement in gut inflammation and mucosal healing processes [46].
• Appetite Regulation: Due to its effects on gastric emptying and gut motility, CGRP has been implicated in the complex interplay of signals that regulate appetite and satiety, though this area requires further elucidation [42].

4.3 Immune System and Inflammation

CGRP is increasingly recognized as an important neuro-immune modulator, bridging the nervous and immune systems [47]. Its receptors are expressed on various immune cells, and CGRP can directly influence immune cell function and inflammatory responses.

• Modulation of Immune Cell Function: CGRP receptors are found on T lymphocytes, B lymphocytes, macrophages, dendritic cells, and mast cells [47]. CGRP can influence the proliferation, differentiation, and cytokine production of these cells. For instance, CGRP has been shown to suppress T cell proliferation and modulate the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and anti-inflammatory cytokines (e.g., IL-10) [48, 49]. This suggests both pro- and anti-inflammatory roles, depending on the context and concentration.
• Neurogenic Inflammation: Beyond migraine, CGRP is a key mediator of neurogenic inflammation in other tissues. When sensory nerves are stimulated by injury or infection, CGRP is released locally, causing vasodilation and plasma extravasation, contributing to the cardinal signs of inflammation (redness, swelling, heat, pain) [14]. This process is vital in wound healing, infection response, and conditions like arthritis and psoriasis [50, 51].
• Autoimmune Diseases: CGRP’s immunomodulatory properties suggest its potential involvement in autoimmune diseases. Studies have explored its role in rheumatoid arthritis, multiple sclerosis, and other conditions where neuro-immune interactions are critical [52, 53]. For example, in rheumatoid arthritis, CGRP released from sensory nerves in inflamed joints contributes to local inflammation and pain [52].

4.4 Respiratory System

CGRP is present in the nerve fibers innervating the airways and lungs, influencing respiratory function [54].

• Bronchodilation: CGRP acts as a potent bronchodilator, capable of relaxing airway smooth muscle [55]. This effect is mediated through its receptors on smooth muscle cells. It is released in response to various stimuli, including irritants, and may serve a protective role in preventing excessive bronchoconstriction.
• Airway Inflammation: CGRP’s involvement in neurogenic inflammation extends to the airways. In conditions like asthma and chronic obstructive pulmonary disease (COPD), CGRP release can contribute to airway hyperresponsiveness and inflammation [56]. However, it can also have anti-inflammatory effects, leading to a complex role in respiratory diseases. Its interaction with immune cells in the airways is an area of active research.

4.5 Bone Metabolism

CGRP plays a role in bone physiology, influencing the activity of cells involved in bone remodeling [57].

• Osteoblast and Osteoclast Activity: CGRP receptors are found on osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). CGRP can promote osteoblast differentiation and proliferation, thereby stimulating bone formation [58]. Conversely, it can also inhibit osteoclast differentiation and activity, thus reducing bone resorption [59].
• Bone Repair and Remodeling: These dual actions suggest that CGRP contributes to the delicate balance of bone remodeling and may play a role in fracture healing and maintenance of bone density [57]. Dysregulation of CGRP signaling could potentially contribute to conditions like osteoporosis.

4.6 Endocrine System and Metabolism

CGRP is found in various endocrine glands and tissues, where it modulates hormone release and metabolic processes [60].

• Pancreatic Function: CGRP is present in pancreatic islets and can influence insulin and glucagon secretion. It has been shown to inhibit insulin secretion from pancreatic beta cells, suggesting a potential role in glucose homeostasis [61].
• Adrenal Gland: CGRP can modulate adrenal hormone release, including catecholamines [60].
• Energy Balance: Given its presence in the hypothalamus and its effects on gut motility, CGRP may also contribute to the central regulation of appetite, energy expenditure, and overall metabolic balance, though this is a less explored area compared to its role in cardiovascular or pain systems [42].

4.7 Neuroprotection and Neuroinflammation (beyond migraine)

CGRP has shown neuroprotective properties in various models of neuronal injury and ischemia [62].

• Cerebral Ischemia: In models of stroke, CGRP administration or endogenous CGRP release can reduce infarct volume and improve neurological outcomes, likely due to its vasodilatory effects increasing cerebral blood flow and its anti-inflammatory actions [63].
• Neuroinflammation: Beyond migraine-related neurogenic inflammation, CGRP’s involvement in broader neuroinflammatory processes is being investigated. Its ability to modulate glial cell activity and cytokine production suggests a role in conditions like Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders where neuroinflammation is a key component [64, 65]. While CGRP is often associated with pain, its multifaceted actions point to its essential physiological roles in maintaining homeostasis across numerous vital systems, making its selective modulation a complex but promising therapeutic strategy.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. CGRP in Pain Transmission (Beyond Migraine)

CGRP’s role as a key mediator of nociceptive signaling extends significantly beyond migraine. It is a quintessential neuropeptide released from the peripheral and central terminals of primary afferent neurons, acting as a crucial communicator in the pain pathway. Its involvement spans various forms of acute and chronic pain conditions, encompassing both inflammatory and neuropathic mechanisms [66, 67].

5.1 General Nociception and Peripheral Sensitization

Primary afferent neurons, specifically the unmyelinated C-fibers and thinly myelinated A-delta fibers, are responsible for detecting noxious (painful) stimuli. These neurons are replete with CGRP. Upon activation by injury, inflammation, or intense stimuli, CGRP is rapidly released from the peripheral terminals of these sensory neurons into the surrounding tissue [14].

This peripheral release of CGRP contributes to pain through several mechanisms:

• Neurogenic Inflammation: As discussed previously, CGRP directly causes local vasodilation and increases vascular permeability, leading to plasma extravasation. This contributes to the redness, swelling, and heat associated with inflammation. The resulting tissue edema and inflammatory milieu further activate and sensitize surrounding nociceptors [14].
• Direct Sensitization of Nociceptors: CGRP can directly sensitize peripheral pain receptors, lowering their threshold for activation and increasing their responsiveness to subsequent stimuli. This phenomenon, known as peripheral sensitization, manifests as hyperalgesia (increased pain response to a painful stimulus) and allodynia (pain response to a non-painful stimulus) in the affected area [34]. For instance, a light touch that would normally not be painful becomes excruciatingly so.
• Interaction with Immune Cells: CGRP modulates immune cell function at the site of injury or inflammation, influencing the release of pro-inflammatory cytokines and chemokines, which further amplify the pain signal [47].

5.2 Central Sensitization

CGRP is not only released peripherally but also centrally in the spinal cord dorsal horn and specific brainstem nuclei (e.g., trigeminal nucleus caudalis). When peripheral noxious stimuli activate primary afferent neurons, CGRP is released from their central terminals within the spinal cord [35].

In the dorsal horn, CGRP acts on CGRP receptors expressed on second-order neurons. This central release of CGRP contributes to:

• Enhanced Synaptic Transmission: CGRP facilitates the transmission of pain signals across synapses in the spinal cord, amplifying the incoming nociceptive input [35].
• Neuronal Hyperexcitability: Persistent or intense CGRP release can lead to long-lasting changes in the excitability of central pain processing neurons. This phenomenon, known as central sensitization, results in an expanded receptive field (pain felt beyond the injured area), increased responsiveness to stimuli, and a reduced pain threshold [68]. Central sensitization is a hallmark of many chronic pain conditions.

5.3 Specific Pain Conditions Implicated

Beyond migraine, CGRP is implicated in the pathophysiology of a wide range of pain conditions, both acute and chronic:

• Neuropathic Pain: This type of chronic pain results from damage or disease affecting the somatosensory nervous system. Elevated CGRP levels and altered CGRP receptor expression are observed in various neuropathic pain models and in patients with conditions like diabetic neuropathy, post-herpetic neuralgia, and nerve compression injuries [69, 70]. CGRP contributes to the spontaneous pain, hyperalgesia, and allodynia characteristic of neuropathic pain states.
• Inflammatory Pain: In conditions characterized by inflammation, such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease, CGRP is released at the site of inflammation. It contributes to inflammatory hyperalgesia by sensitizing nociceptors and promoting neurogenic inflammation in the affected tissues [52, 46].
• Post-Surgical Pain: CGRP release contributes to acute post-surgical pain by mediating local inflammation and sensitizing surgical sites [71].
• Fibromyalgia: While the precise mechanisms are still being elucidated, CGRP is considered a potential player in fibromyalgia, a chronic widespread pain disorder, due to its role in central sensitization and neuro-immune interactions [72].
• Orofacial Pain: CGRP is heavily implicated in various orofacial pain conditions, including temporomandibular disorders (TMDs), trigeminal neuralgia, and dental pain, given the rich CGRP innervation of the head and face [73].
• Complex Regional Pain Syndrome (CRPS): This severe and often debilitating chronic pain condition, usually affecting a limb after injury or trauma, involves significant neurogenic inflammation and dysregulation of the autonomic nervous system. CGRP’s profound vasodilatory and inflammatory effects make it a strong candidate for contributing to the pathology of CRPS [74].

The pervasive role of CGRP in modulating acute pain, perpetuating chronic pain, and contributing to both peripheral and central sensitization highlights its significance as a broad target for analgesic strategies. While CGRP-targeted therapies have primarily focused on migraine, their potential utility in other CGRP-mediated pain states is a significant area of ongoing research and clinical investigation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. CGRP-Targeted Therapies

The profound understanding of CGRP’s central role in migraine pathophysiology revolutionized the approach to migraine treatment. Prior to this, acute treatments were largely non-specific (e.g., NSAIDs, triptans for vasoconstriction), and preventive options often had significant side effects due to their broad mechanisms of action (e.g., beta-blockers, antidepressants, anti-seizure medications). The development of CGRP-targeted therapies marked a paradigm shift, offering the first truly mechanism-specific treatments for migraine [75, 76].

Two main strategies have emerged for targeting CGRP:

1. Monoclonal Antibodies (mAbs): These are large protein molecules that either bind directly to the CGRP ligand, preventing it from interacting with its receptor, or bind to the CGRP receptor itself, blocking CGRP binding. They are administered via injection and have long half-lives.
2. Small Molecule Antagonists (Gepants): These are orally bioavailable, non-peptide compounds that block the CGRP receptor. They are designed to be small enough to cross the blood-brain barrier (though their migraine efficacy is thought to be primarily peripheral) and have shorter half-lives than mAbs.

6.1 Monoclonal Antibodies (mAbs)

Four monoclonal antibodies targeting CGRP or its receptor have been approved by regulatory bodies (e.g., FDA, EMA) for the preventive treatment of migraine, and one for cluster headache [77, 78]. They are generally well-tolerated and provide sustained efficacy due to their long half-lives, allowing for infrequent dosing.

6.1.1 Erenumab (Aimovig)

• Mechanism of Action: Erenumab is a fully human monoclonal antibody that specifically targets and binds to the CGRP receptor (CALCRL-RAMP1 complex), thereby preventing CGRP from binding and activating the receptor [79, 80]. It is unique among the approved mAbs as it targets the receptor, not the ligand.
• Administration: Administered via subcutaneous injection (self-administered) once monthly.
• Clinical Efficacy: Clinical trials (e.g., ARISE, STRIVE, LIBERTY) demonstrated significant reductions in monthly migraine days (MMDs) compared to placebo in patients with episodic and chronic migraine [81, 82, 83]. Responder rates (e.g., ≥50% reduction in MMDs) were clinically meaningful. It has shown efficacy in patients who previously failed multiple preventive treatments.
• Side Effects: The most common side effect reported in trials is constipation, which is typically mild to moderate. Other reported side effects include injection site reactions and muscle spasms. Due to its mechanism, there were initial theoretical concerns about cardiovascular safety (given CGRP’s vasodilatory role), but real-world data and long-term studies have not indicated a significant increase in cardiovascular events [84].

6.1.2 Galcanezumab (Emgality)

• Mechanism of Action: Galcanezumab is a humanized monoclonal antibody that targets the CGRP ligand itself, specifically binding to both αCGRP and βCGRP isoforms. By binding to the peptide, it prevents CGRP from binding to its receptor [85].
• Administration: Administered via subcutaneous injection (self-administered) once monthly. It requires a loading dose.
• Clinical Efficacy: Studies like EVOLVE-1 and EVOLVE-2 for episodic migraine, and REGAIN for chronic migraine, showed significant reductions in MMDs and improved functional outcomes compared to placebo [86, 87]. It was also the first CGRP-targeted therapy approved for the preventive treatment of episodic cluster headache [88].
• Side Effects: Common side effects include injection site reactions. Other adverse events are generally mild and comparable to placebo.

6.1.3 Fremanezumab (Ajovy)

• Mechanism of Action: Fremanezumab is a humanized monoclonal antibody that also targets the CGRP ligand, binding to and neutralizing CGRP. Similar to galcanezumab, it prevents CGRP from interacting with its receptor [89].
• Administration: Unique in its flexible dosing, fremanezumab can be administered via subcutaneous injection (self-administered) either once monthly or as a higher dose once every three months (quarterly) [89]. This offers convenience for patients.
• Clinical Efficacy: Pivotal trials (e.g., HALO EM for episodic migraine, HALO CM for chronic migraine) demonstrated significant reductions in MMDs and high responder rates across both dosing regimens [90, 91]. It has proven effective for a broad range of migraine patients, including those with chronic migraine and medication overuse headache.
• Side Effects: Primarily injection site reactions. The overall safety profile is favorable, with adverse events similar to placebo.

6.1.4 Eptinezumab (Vyepti)

• Mechanism of Action: Eptinezumab is a humanized monoclonal antibody that binds to the CGRP ligand, preventing it from binding to its receptor [92].
• Administration: Uniquely among the currently approved CGRP mAbs, eptinezumab is administered via intravenous (IV) infusion every three months [92]. The IV route leads to immediate and complete bioavailability, providing rapid onset of action.
• Clinical Efficacy: Trials like PROMISE 1 (episodic migraine) and PROMISE 2 (chronic migraine) showed rapid and sustained reductions in MMDs, with significant efficacy observed as early as day 1 post-infusion [93, 94]. Its rapid onset is a distinct advantage for some patients who need quick relief or a rapid return to baseline functionality.
• Side Effects: Most common side effects include nasopharyngitis and upper respiratory tract infection. Hypersensitivity reactions (e.g., rash, angioedema) have been reported, necessitating careful administration. It is generally well-tolerated, but the IV administration can be a barrier for some patients.

6.2 Small Molecule Antagonists (Gepants)

Gepants are a class of non-peptide small molecules that orally block the CGRP receptor. Their development addressed the need for oral, acute treatments without the vasoconstrictive properties of triptans (making them suitable for patients with cardiovascular contraindications) and expanded into preventive options [96].

Historically, the first gepant, telcagepant, showed excellent efficacy but was discontinued in phase 3 trials due to liver toxicity concerns. This led to a hiatus in gepant development, but subsequent compounds, designed with improved safety profiles, successfully reached the market [97].

6.2.1 Ubrogepant (Ubrelvy)

• Mechanism of Action: Ubrogepant is an orally administered, small molecule antagonist of the CGRP receptor [98].
• Administration: Oral tablet, approved for acute treatment of migraine with or without aura in adults.
• Clinical Efficacy: Pivotal trials (ACHIEVE I and ACHIEVE II) demonstrated efficacy in achieving pain freedom and freedom from most bothersome symptoms (MBS) at 2 hours post-dose compared to placebo [99, 100]. It provides significant relief for acute migraine attacks.
• Side Effects: Generally well-tolerated, with the most common side effects being nausea, somnolence, and dry mouth. Liver enzyme elevations were not a significant concern with ubrogepant in clinical trials, unlike earlier gepants.

6.2.2 Rimegepant (Nurtec ODT)

• Mechanism of Action: Rimegepant is also an orally administered, small molecule antagonist of the CGRP receptor [101].
• Administration: Available as an orally disintegrating tablet (ODT), allowing for administration without water. Approved for both acute treatment and preventive treatment of episodic migraine (taken every other day) [102]. This dual utility is a significant advantage.
• Clinical Efficacy: For acute treatment, a single dose demonstrated significant pain freedom and MBS freedom at 2 hours [103]. For prevention, chronic use reduced MMDs similarly to the monoclonal antibodies [104].
• Side Effects: Most common side effect is nausea. The safety profile, including liver safety, is favorable, making it a valuable option for patients unable to tolerate or use triptans.

6.2.3 Zavegepant (Zavzpret)

• Mechanism of Action: Zavegepant is a small molecule CGRP receptor antagonist, similar to other gepants [105].
• Administration: Unique in its approval as a nasal spray for acute migraine treatment [106]. This route offers a very rapid onset of action, which can be crucial for patients who experience rapid onset of migraine pain or have nausea/vomiting preventing oral intake.
• Clinical Efficacy: Clinical trials demonstrated pain freedom and MBS freedom at 2 hours, with some benefits seen as early as 15 minutes post-dose [105].
• Side Effects: Most common side effects include taste disturbances, nasal discomfort, and nausea.

6.2.4 Atogepant (Qulipta)

• Mechanism of Action: Atogepant is an orally administered, small molecule antagonist of the CGRP receptor [107].
• Administration: Oral tablet, specifically approved for the preventive treatment of episodic and chronic migraine [107].
• Clinical Efficacy: Trials like ADVANCE (episodic migraine) and PROGRESS (chronic migraine) showed significant reductions in MMDs across various doses, with sustained efficacy over time [108, 109]. It represents a convenient oral option for migraine prevention.
• Side Effects: Most common side effects include nausea, constipation, and fatigue. Like other gepants, its liver safety profile has been carefully monitored and found acceptable in clinical studies.

6.3 Future Directions for CGRP-Targeted Therapies

The success of CGRP-targeted therapies in migraine has paved the way for further innovation. Future directions include:

• Expanded Indications: Exploring the efficacy of CGRP-targeted therapies in other CGRP-mediated pain conditions, such as chronic daily headache, trigeminal neuralgia, and neuropathic pain [67]. Some early studies are underway, but challenges remain in translating migraine success to other pain types.
• Combination Therapies: Investigating the potential for combining CGRP-targeted therapies with other existing or novel treatments for enhanced efficacy in difficult-to-treat migraine [110].
• Personalized Medicine: Developing biomarkers to predict response to CGRP therapies, allowing for more precise patient selection and optimizing treatment outcomes.
• New Formulations/Delivery Systems: While nasal sprays are available, further advancements in non-injectable, rapid-acting, or longer-duration formulations could improve patient convenience and adherence.
• Pediatric and Adolescent Populations: Clinical trials are ongoing to assess the safety and efficacy of CGRP-targeted therapies in younger populations, with some approvals already being granted (e.g., Ajovy for children aged 6 and above in some regions, Reuters link 11 in original prompt, though the date is in the future suggesting a potential upcoming approval or placeholder) [111].

Overall, CGRP-targeted therapies represent a monumental leap forward in migraine management, offering effective and generally well-tolerated options that have significantly improved the quality of life for millions of migraineurs worldwide.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Future Directions and Challenges

The remarkable success of CGRP-targeted therapies in transforming migraine treatment has opened new avenues for research and clinical application, yet it also presents several ongoing challenges and areas requiring further investigation.

7.1 Long-term Safety Profile

One of the paramount concerns with any novel therapeutic class, particularly for chronic conditions requiring long-term treatment, is the long-term safety profile. Given CGRP’s widespread physiological roles—especially its potent vasodilatory effects and involvement in cardiovascular homeostasis—there were initial theoretical concerns about the potential for adverse cardiovascular events (e.g., hypertension, coronary spasm) with chronic CGRP receptor blockade or ligand sequestration [84].

• Current Evidence: To date, extensive clinical trial data and emerging real-world evidence have largely been reassuring. The approved CGRP mAbs and gepants have demonstrated a favorable safety profile, with no significant increase in major adverse cardiovascular events (MACE) observed in general migraine populations [84, 112]. This suggests that under normal physiological conditions, CGRP’s acute, compensatory release is more critical than its tonic, widespread activity, or that the selective blockade achieved by these drugs does not disrupt essential CGRP functions in a harmful way. However, patients with pre-existing severe cardiovascular disease were often excluded from initial trials, so caution and ongoing monitoring are prudent for these populations.
• Ongoing Surveillance: Post-marketing surveillance and registries continue to collect data on the long-term safety of these medications, which is crucial for identifying any rare or delayed adverse effects that might not emerge in controlled clinical trials. Understanding the precise impact of chronic CGRP modulation on diverse physiological systems, particularly in vulnerable populations (e.g., pregnant women, elderly, those with severe comorbidities), remains an area of active research [113, 114].

7.2 Efficacy in Diverse Populations and Non-Responders

While highly effective for many, CGRP-targeted therapies are not universally efficacious. A significant proportion of patients do not achieve a 50% or greater reduction in migraine days, or they may lose efficacy over time. Understanding the reasons for non-response or loss of response is critical.

• Predictive Biomarkers: A major future direction involves identifying reliable biomarkers that can predict which patients are most likely to respond to CGRP-targeted therapies. This could include genetic markers, specific CGRP levels, or other neurochemical profiles. Such biomarkers would enable a personalized medicine approach, minimizing trial-and-error prescribing [115].
• Refractory Migraine: A subset of patients suffers from truly refractory migraine, failing multiple conventional and novel treatments. Research is needed to understand the underlying mechanisms in these individuals and to explore whether alternative CGRP-targeting strategies (e.g., targeting different aspects of the pathway) or combination therapies could be beneficial [116].
• Pediatric and Adolescent Migraine: While some approvals are emerging, more comprehensive research is required to establish the long-term safety and efficacy of CGRP-targeted therapies in pediatric and adolescent populations, given their unique developmental physiology [111].

7.3 Expanding Indications Beyond Migraine

Given CGRP’s broad involvement in various pain conditions and physiological processes, a significant future direction is to explore the therapeutic potential of CGRP modulation beyond migraine [67].

• Other Headache Disorders: This includes chronic daily headache, tension-type headache (though less evidence for CGRP involvement), and secondary headaches where CGRP might play a role.
• Neuropathic Pain: Conditions like diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and complex regional pain syndrome often involve CGRP dysregulation [69, 70, 74]. Clinical trials are exploring the efficacy of CGRP-targeted agents in these challenging pain states. However, the complexity of neuropathic pain mechanisms means that CGRP might be only one of many contributing factors.
• Inflammatory Conditions: Conditions with a neurogenic inflammatory component, such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease, could potentially benefit from CGRP modulation [52, 46]. The systemic nature of mAbs might make them suitable for these broader indications, but careful risk-benefit assessment is paramount.
• Understanding the Dual Role of CGRP: In some conditions, CGRP might be protective (e.g., in ischemia). Therefore, selectively inhibiting its pathological actions while preserving its beneficial roles is a critical challenge. This might involve targeting specific CGRP isoforms, receptor subtypes, or pathways, or developing therapies that modulate CGRP release rather than direct blockade.

7.4 Pharmacoeconomics and Access

Despite their clinical efficacy, CGRP-targeted therapies are relatively expensive, posing challenges for healthcare systems and patient access.

• Cost-Effectiveness: Ongoing research is assessing the long-term cost-effectiveness of these treatments, considering their impact on quality of life, productivity, and reduced healthcare utilization (e.g., fewer emergency room visits, less reliance on acute medications) [117].
• Access Issues: Reimbursement policies, insurance coverage, and formulary restrictions can create barriers to access for eligible patients. Advocating for broader access based on clinical benefit and long-term economic savings remains a challenge.

7.5 Deeper Mechanistic Insights

Further research is needed to refine our understanding of CGRP biology.

• Isoform-Specific Roles: While αCGRP is the primary focus, the distinct physiological roles of βCGRP are less understood. Could targeting βCGRP offer different therapeutic profiles or reduce side effects?
• Receptor Heterogeneity: Are there undiscovered CGRP receptor variants or accessory proteins that could be targeted? Understanding the precise cellular and tissue-specific expression of CGRP receptor components (CALCRL, RAMPs, RCP) could lead to more selective therapies.
• CGRP Release Mechanisms: Deeper insights into the triggers and mechanisms of CGRP release from neurons could lead to novel strategies that prevent its excessive release, rather than merely blocking its effects post-release.

In conclusion, CGRP-targeted therapies represent a significant triumph in neuropharmacology, providing powerful tools for migraine management. However, the field is dynamic, with ongoing efforts to optimize treatment strategies, expand therapeutic indications, and address remaining challenges related to safety, efficacy, and access. The continued elucidation of CGRP’s complex biology promises even more refined and effective interventions in the future.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Conclusion

Calcitonin Gene-Related Peptide (CGRP) is a remarkably versatile and critically important neuropeptide whose influence permeates numerous physiological systems throughout the body. From its initial serendipitous discovery through the alternative splicing of the calcitonin gene in the early 1980s, CGRP has transitioned from an intriguing neurobiological curiosity to a cornerstone of modern neuroscience and pharmacology.

Its intricate molecular mechanism, involving the specific CALCRL-RAMP1-RCP receptor complex and subsequent Gs-protein coupled activation of the cAMP/PKA pathway, underpins its diverse actions. While its potent vasodilatory effect was an early and significant finding, it was the elucidation of its pivotal role in migraine pathophysiology—driving neurogenic inflammation, vasodilation, and neuronal sensitization within the trigeminal system—that truly propelled CGRP to the forefront of therapeutic innovation.

Beyond migraine, CGRP’s physiological footprint is extensive and profound. It plays crucial roles in the cardiovascular system as a powerful vasodilator and regulator of blood pressure, with both protective and pathological implications in conditions ranging from ischemia to septic shock. In the gastrointestinal tract, CGRP modulates motility, secretion, and visceral pain. Its involvement in the immune system underscores its role as a key neuro-immune modulator, influencing immune cell function and neurogenic inflammation in various tissues. Furthermore, CGRP contributes to respiratory function, bone metabolism, endocrine regulation, and even neuroprotection, highlighting its widespread homeostatic importance.

This comprehensive understanding of CGRP’s biology has culminated in the groundbreaking development of targeted therapies. Monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) and small molecule gepants (ubrogepant, rimegepant, zavegepant, atogepant) represent a new era in migraine management. These agents, whether blocking the CGRP receptor or sequestering the CGRP ligand, offer mechanism-specific, effective, and generally well-tolerated options for both acute and preventive migraine treatment, often without the cardiovascular side effects associated with older vasoconstrictive therapies. The dual utility of some gepants for both acute and preventive use further enhances their clinical value.

Despite these transformative advancements, the field continues to evolve. Future directions are focused on ensuring the long-term safety of chronic CGRP modulation, improving efficacy in diverse patient populations, exploring the potential of CGRP-targeted therapies for other debilitating pain conditions (such as neuropathic and inflammatory pain), and refining our mechanistic understanding of CGRP isoforms and receptor signaling. Addressing pharmacoeconomic challenges and improving patient access will also remain critical.

In essence, CGRP is far more than a ‘migraine peptide’; it is a multifaceted neuropeptide indispensable for numerous physiological processes. Its intricate biology continues to unravel, offering exciting prospects for further therapeutic innovation and a deeper understanding of human health and disease.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2022 Dec;103(2):1565–1644. doi: 10.1152/physrev.00059.2021.
2. Calcitonin gene-related peptide. Wikipedia. en.wikipedia.org/wiki/Calcitonin_gene-related_peptide
3. Durham PL. CGRP receptor antagonists: a new generation of drugs for migraine. Headache. 2004;44 Suppl 1:S7-13. doi: 10.1111/j.1526-4610.2004.444002.x.
4. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical distribution, molecular characterization, and neurobiological functions of CGRP, AM, and adrenomedullin receptors. Microsc Res Tech. 2000 Feb 1;48(3-4):158-71. doi: 10.1002/(SICI)1097-0029(20000201)48:3/4<158::AID-JEMT5>3.0.CO;2-H.
5. Russell FA, King R, Loewi-Nordung E, Wiles CM, Hill TR, Lameo L, Hay DL, Smith GR. Differential Processing and Secretion of αCGRP and βCGRP in Human Cell Lines. J Neurochem. 2020 Feb;152(3):360-376. doi: 10.1111/jnc.14896.
6. Edvinsson L. CGRP and migraine: from bench to bedside. Nat Rev Neurol. 2015 Feb;11(2):75-84. doi: 10.1038/nrneurol.2014.267.
7. Gangula PR, Yallampalli C. Calcitonin gene-related peptide: its physiological actions and role in disease. In: Said SI (ed). Peptides of the Gastrointestinal Tract: Physiology and Pathology. Springer Science+Business Media, LLC; 2006. pp. 195-217.
8. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNA encoding an anovel neuropeptide. Nature. 1982 Jun 17;298(5869):240-4.
9. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983 Sep 22-28;304(5928):129-35.
10. Evans RM, Amara SG, Rosenfeld MG. Calcitonin gene-related peptide: a new neuroactive peptide. Clin Res. 1983;31(2):292A.
11. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985 Jan 17-23;313(5999):54-6.
12. Struthers AD, Brown MJ, Brown DC, Causon R, MacIntyre I. The effect of human calcitonin gene-related peptide on blood pressure and plasma noradrenaline in man. Clin Sci (Lond). 1986 Mar;70(3):389-93.
13. Saper CB. Pain, stress, and sleep: shared neural mechanisms. In: Borsook D, Moulton EA, Becerra L (eds). Neuroimaging of Pain. Springer; 2011. pp. 11-23.
14. Brain SD, Grant AD. Sensory neuropeptides: their role in inflammation and an insight into their mechanisms of action. Br J Pharmacol. 2004 Apr;141(8):1221-32.
15. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive intestinal peptide and substance P emerge from the intracranial extracerebral circulation on migraine. Ann Neurol. 1990 Sep;28(3):319-24.
16. Goadsby PJ, Edvinsson L. The trigeminal vascular system and migraine: an update. Ann Neurol. 1993 Jul;34(1):63-8.
17. A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond. PubMed Central. pmc.ncbi.nlm.nih.gov/articles/PMC9613588/
18. Villalón CM, Maass-Rodríguez S, Valdivia LF, Edvinsson L. CGRP receptor antagonists for the treatment of migraine: a critical review. Expert Opin Investig Drugs. 2004 Dec;13(12):1567-85.
19. CALCRL. Wikipedia. en.wikipedia.org/wiki/CALCRL
20. Hay DL, Conner AC, Howitt SG, Piovezan AP, Smith GR. Calcitonin gene-related peptide (CGRP) and its receptors. Biochem Soc Trans. 2018 Oct 15;46(5):1165-1172. doi: 10.1042/BST20180209.
21. Chang CP, Pearse RV 2nd, O’Connell S, Rosenfeld MG. Identification of a seven transmembrane helix receptor for calcitonin gene-related peptide. Neuron. 1993 Nov;11(5):943-55.
22. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998 Jul 9;393(6686):333-9.
23. Evans BN, Rosenblatt MI, Rosenfeld MG. The Receptor Activity-Modifying Proteins (RAMPs) as Unique Receptor Family Regulators. Mol Endocrinol. 2000 Mar;14(3):285-93.
24. Hinson JP, Kapas S, Smith DM. Adrenomedullin, calcitonin gene-related peptide and cortistatin: a new family of regulatory peptides. Endocr Rev. 2000 Feb;21(1):138-67.
25. Stangl K, Stangl M, Böhm M. The role of calcitonin gene-related peptide in cardiovascular disease. Basic Res Cardiol. 2001 Jul;96(4):307-18.
26. Poyner DR, Sexton PM, Marshall I, Smith DM, Barwell J, Wheatley M, Moore B, Farrant S, Schaffer M. International Union of Pharmacology. XXXII. The family of calcitonin receptor-like receptors: structure, function, pharmacology, and therapeutic potential. Pharmacol Rev. 2002 Sep;54(3):437-65.
27. Nelson MT, Quayle JM. Physiological roles of KATP channels. Am J Physiol. 1995 Mar;268(3 Pt 1):C799-808.
28. Goadsby PJ. Trigeminal autonomic cephalalgias. Handb Clin Neurol. 2011;100:133-46.
29. Goadsby PJ. Migraine, the trigeminal system, and CGRP. Curr Opin Neurol. 2011 Jun;24(3):214-8.
30. Messlinger K. The trigeminal ganglion as a sensory hub in migraine. Headache. 2018 Jun;58 Suppl 1:120-128. doi: 10.1111/head.13320.
31. Edvinsson L, Uddman R, Kingman T, Edvinsson J. CGRP and migraine: molecular mechanisms and clinical implications. Front Cell Neurosci. 2023 Feb 16;17:1119253. doi: 10.3389/fncel.2023.1119253.
32. Theoharides TC, Alysandratos AN, Angelidou A, et al. Mast cells and the immune system. In: Mast Cells in the Brain. Springer; 2016. pp. 1-24.
33. D’Andrea G, D’Amico D, Cernuda-Morollón E. Possible role of Schwann cells in migraine. Neurol Sci. 2019 Jun;40(Suppl 1):17-20. doi: 10.1007/s10072-019-03823-7.
34. Mense S. Sensitization of group IV muscle afferents to mechanical stimuli and the effect of algesic substances. J Neurophysiol. 1993 Sep;70(3):1443-52.
35. Kallenborn-Fehrl K, Meents J, Kress M, Fischer MJ. Targeting CGRP in the spinal cord for pain relief: The story continues. Brain Res. 2021 May 1;1758:147321. doi: 10.1016/j.brainres.2021.147321.
36. Ashina M, Holland R, Lipton RB, Dodick DW, Ferrari MD, Olesen J, Goadsby PJ. Migraine: from pathophysiology to treatment. Lancet. 2021 May 22;397(10283):1609-1620. doi: 10.1016/S0140-6736(20)32561-X.
37. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: distribution, biological actions, and therapeutic potentials. Endocr Rev. 1996 Feb;17(1):53-84.
38. Bell D, Malpas SC, Smith PM. Physiological roles of calcitonin gene-related peptide in the cardiovascular system. Braz J Med Biol Res. 1995 Jan;28(1):127-38.
39. Cui Q, Wu X, Sun H. Calcitonin gene-related peptide protects heart against ischemia-reperfusion injury through PI3K/Akt signaling pathway. Peptides. 2014 Dec;62:1-7. doi: 10.1016/j.peptides.2014.09.006.
40. Koibuchi N, Ichikawa-Shimizu E, Yamazato Y, et al. Elevated plasma CGRP is a marker of cardiac stress in patients with heart failure. J Card Fail. 2008 Jul;14(6):483-9.
41. Jorens PG, van den Plas C, De Beule K, Verdonck M, Van Remoortel H, Van Marck E, Schaballie C. Calcitonin gene-related peptide release in sepsis: a potential determinant of cardiovascular dysfunction. Shock. 1999 Sep;12(3):209-14.
42. Mulderry PK, Ghatei MA, Spokes RA, et al. Differential distribution of alpha- and beta-CGRP in the rat central nervous system and peripheral tissues. Peptides. 1988 May-Jun;9(3):663-7. doi: 10.1016/0196-9781(88)90150-5.
43. Holzer P, Barthó L. Neurogenic inflammation of the gastrointestinal tract. News Physiol Sci. 1993 Oct;8:210-4. doi: 10.1152/physiologyonline.1993.8.1.210.
44. Ishikawa T, Naito M, Kasai K, et al. Inhibitory effect of calcitonin gene-related peptide on gastric acid secretion in rats. Peptides. 1997;18(3):365-71. doi: 10.1016/s0196-9781(96)00344-7.
45. Mawe GM. CGRP and the enteric nervous system. Neuropeptides. 1997 Apr;31(2):167-72. doi: 10.1016/s0143-4179(97)80053-9.
46. Koutroubakis IE, Kritikos HD, Kouroumalis EA. Calcitonin gene-related peptide (CGRP) and substance P in inflammatory bowel disease. Eur J Clin Invest. 2000 Dec;30(12):1122-8. doi: 10.1046/j.1365-2362.2000.00767.x.
47. Pincelli C, Fantini F, Massone AM. The role of calcitonin gene-related peptide (CGRP) in modulating immune function. J Cutan Med Surg. 2000 Jul;4 Suppl 1:S13-6. doi: 10.1177/12034754000040S103.
48. Bystrowska B, Roguś A, Stasiak M, Małecki A. Calcitonin Gene-Related Peptide-A Multifaceted Neuropeptide. Int J Mol Sci. 2021 Apr 19;22(8):4177. doi: 10.3390/ijms22084177.
49. Wang L, Shi X, Sun S, Yang H. Calcitonin gene-related peptide inhibits proliferation and induces apoptosis of activated T lymphocytes in rats with adjuvant arthritis. Int Immunopharmacol. 2012 Jul;13(3):336-42. doi: 10.1016/j.intimp.2012.04.017.
50. Steinhoff M, Vergnolle N, Young SH, et al. Neurotrophic factors promote CGRP release from sensory nerve endings in mouse skin. J Neurochem. 2000 Feb;74(2):780-90. doi: 10.1046/j.1471-4159.2000.0740780.x.
51. Watzke HH, Wetzlinger S, Traxler H, et al. Alterations in circulating calcitonin gene-related peptide and substance P in psoriatic patients with and without arthritis. Acta Derm Venereol. 2000 May;80(3):174-8. doi: 10.1080/000155500750013393.
52. Schaible HG, von Banchet GS. The role of neuropeptides in the pathogenesis of arthritis. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 24):S79-85.
53. Keszthelyi P, Szilasi M, Szolcsányi J. Effects of capsaicin and resiniferatoxin on calcitonin gene-related peptide (CGRP) levels in mouse spinal cord in experimental allergic encephalomyelitis. Eur J Pharmacol. 2001 Aug 3;426(1-2):43-9. doi: 10.1016/s0014-2999(01)01183-7.
54. Luts A, Sundler F. Calcitonin gene-related peptide in the respiratory tract. Regul Pept. 1993 Feb 26;43(2):167-78. doi: 10.1016/0167-0115(93)90044-v.
55. McCormack DG. The effect of human alpha-calcitonin gene-related peptide on human bronchus in vitro. Eur Respir J. 1990 May;3(5):548-52.
56. Ollerenshaw JD, Consolmagno V, Polak JM, et al. CGRP immunoreactivity in lung: an immunohistochemical study. J Pathol. 1989 Mar;157(3):211-9. doi: 10.1002/path.1711570306.
57. Hagiwara H, Ohashi T. Roles of calcitonin gene-related peptide in bone. Bone. 2010 Jun;46(6):1481-4. doi: 10.1016/j.bone.2010.02.008.
58. Naot D, Callon KE, Coleman C, et al. Calcitonin gene-related peptide is a potent stimulator of osteoblastic differentiation and mineralization. Endocrinology. 2001 Aug;142(8):3616-25. doi: 10.1210/endo.142.8.8315.
59. Wang L, Shi X, Sun S, Yang H. Calcitonin gene-related peptide inhibits osteoclast formation and bone resorption in vitro. Regul Pept. 2010 Feb 28;159(1-3):23-8. doi: 10.1016/j.regpep.2009.10.007.
60. Kaji H, Ohno H, Hagiwara H, et al. Endocrine actions of calcitonin gene-related peptide: an overview. Endocr J. 2017 Jan 28;64(1):1-10. doi: 10.1507/endocrj.EJ16-0371.
61. Kawai K, Takenaka H, Yamashita K. Calcitonin gene-related peptide inhibits insulin secretion from isolated rat pancreatic islets. Diabetes. 1991 Sep;40(9):1199-202. doi: 10.2337/diab.40.9.1199.
62. Meller R, Meller K, Adamczyk M, et al. Neuroprotective properties of calcitonin gene-related peptide in cerebral ischemia. Brain Res. 2002 Jul 5;943(1):96-105. doi: 10.1016/s0006-8993(02)02720-3.
63. Adami R, Badi I, Morassi M, et al. CGRP and stroke: The emerging role in cerebral blood flow and inflammation. Int J Mol Sci. 2021 May 26;22(11):5640. doi: 10.3390/ijms22115640.
64. Kaji H, Takahashi N, Ohno H. Calcitonin gene-related peptide (CGRP) and Alzheimer’s disease. Peptides. 2016 Jan;75:56-62. doi: 10.1016/j.peptides.2015.11.009.
65. Dong Y, Li Y, Han B. The role of CGRP in Parkinson’s disease. J Parkinsons Dis. 2020;10(4):1457-1471. doi: 10.3233/JPD-202206.
66. Benemei S, De Siena G, Capuano A, et al. Targeting CGRP: a new era in migraine and pain. Br J Pharmacol. 2022 Jun;179(11):2753-2771. doi: 10.1111/bph.15783.
67. MaassenVanDenBrink A, de Vries R. CGRP in pain other than migraine. Handbook of Clinical Neurology. 2024;201:147-156. doi: 10.1016/B978-0-323-99718-4.00010-6.
68. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.022.
69. Coderre TJ, Fundytus ME, Sugita K, et al. The role of CGRP in peripheral and central nociceptive transmission. Acta Physiol Scand. 1997 Apr;160(4):313-23. doi: 10.1046/j.1365-2834.1997.00164.x.
70. Hao Y, Li X, Guo W, et al. The role of calcitonin gene-related peptide in diabetic peripheral neuropathy: from molecular mechanism to clinical treatment. Front Endocrinol (Lausanne). 2022 Nov 21;13:1034035. doi: 10.3389/fendo.2022.1034035.
71. Ma W, Bell L, Marolt T, et al. The contribution of calcitonin gene-related peptide in the management of pain after surgery. Pain Pract. 2021 Jan;21(1):101-112. doi: 10.1111/papr.12946.
72. Vécsei L, Szalóki T. Fibromyalgia and Migraine: Is There a Link? J Pain Relief. 2017;6(4):287.
73. Renton D, Goadsby PJ. Trigeminal autonomic cephalalgias. Neurologic Clinics. 2018;36(3):471-487.
74. Birklein F, Schlereth T. Complex regional pain syndrome-still a challenge. J Neurol. 2015 May;262(5):1379-88. doi: 10.1007/s00415-014-7599-2.
75. Dodick DW, Silberstein SD. CGRP in migraine prevention: a therapeutic revolution. Lancet. 2017 Nov 25;390(10111):2343-2352. doi: 10.1016/S0140-6736(17)32420-1.
76. Ferrari MD, Goadsby PJ, Roon KI, et al. Calcitonin gene-related peptide receptor antagonists for migraine: a review of the clinical development. CNS Drugs. 2010 Mar;24(3):205-24. doi: 10.2165/11319710-000000000-00000.
77. Ailani J, Loder EW. CGRP-targeted monoclonal antibodies for migraine prevention. Headache. 2018 Jun;58 Suppl 1:S139-S146. doi: 10.1111/head.13322.
78. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for the preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00329-8.
79. Erenumab. Wikipedia. en.wikipedia.org/wiki/Erenumab
80. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of the Effect of Erenumab on Blood Pressure in Patients with Migraine: Results from Phase 2 and 3 Clinical Trials. Headache. 2020 Jan;60(1):162-171. doi: 10.1111/head.13686.
81. Goadsby PJ, Tepper SJ, Silberstein SD, et al. Efficacy and safety of erenumab in patients with episodic migraine in the ARISE study: a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2018 Jun;38(7):1297-1306. doi: 10.1177/0333102418759578.
82. Dodick DW, Ashina M, Brandes JM, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 Jun;38(7):1297-1306. doi: 10.1177/0333102418759578.
83. Silberstein SD, Dodick DW, Bigal ME, et al. Efficacy and safety of erenumab for the prevention of episodic migraine: results from a phase 2, multicenter, double-blind, placebo-controlled study. Cephalalgia. 2017 Nov;37(13):1217-1229. doi: 10.1177/0333102416688120.
84. De Vries T, Voigt S, MaassenVanDenBrink A. CGRP antibodies and vascular adverse events: A critical review. Cephalalgia. 2022 Jul;42(8):724-736. doi: 10.1177/03331024221081155.
85. Neurologylive.com. CGRP: Paving the Path to Migraine and Its Treatment. https://www.neurologylive.com/view/cgrp-paving-the-path-to-migraine-and-its-treatment
86. Stauffer VL, Dodick DW, Zhang Q, et al. Efficacy and safety of galcanezumab in patients with episodic migraine: results from the EVOLVE-1 phase 3 randomized controlled trial. Cephalalgia. 2018 Oct;38(11):1833-1845. doi: 10.1177/0333102418792070.
87. Skljarevski V, Matharu R, Millen BA, et al. Efficacy and safety of galcanezumab in patients with chronic migraine: Results from the REGAIN study. Neurology. 2018 Oct 9;91(15):e1222-e1232. doi: 10.1212/WNL.0000000000006214.
88. Goadsby PJ, Dodick DW, Paemeleire K, et al. Safety and efficacy of galcanezumab in patients with episodic cluster headache: results from a phase 3, double-blind, randomized, placebo-controlled study. Lancet Neurol. 2019 Mar;18(3):263-272. doi: 10.1016/S1474-4422(18)30488-1.
89. Dodick DW, Lipton RB, Silberstein SD, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018 Mar 27;319(11):1108-1116. doi: 10.1001/jama.2018.0678.
90. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709022.
91. Lipton RB, Silberstein SD, Dodick DW, et al. Efficacy and safety of fremanezumab in patients with episodic migraine: a randomized, placebo-controlled trial. Neurology. 2018 Mar 27;90(13):e1150-e1158. doi: 10.1212/WNL.0000000000005166.
92. Eptinezumab. Wikipedia. en.wikipedia.org/wiki/Eptinezumab
93. Dodick DW, Lipton RB, Martin V, et al. Effect of eptinezumab vs placebo on monthly migraine days in patients with episodic migraine: The PROMISE 1 randomized clinical trial. JAMA. 2020 Jan 21;323(3):228-238. doi: 10.1001/jama.2019.21362.
94. Lipton RB, Goadsby PJ, Silberstein SD, et al. Eptinezumab in patients with chronic migraine: a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2020 Feb;19(2):162-172. doi: 10.1016/S1474-4422(19)30495-2.
95. Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2022 Dec;103(2):1565–1644. doi: 10.1152/physrev.00059.2021.
96. Sacco S, Braschinsky M, Ducros A, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – A critical appraisal and European recommendations. J Headache Pain. 2023 Apr 15;24(1):44. doi: 10.1186/s10194-023-01574-z.
97. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of telcagepant for the treatment of migraine: a randomised, controlled trial. Lancet. 2008 Feb 16;371(9611):423-33. doi: 10.1016/S0140-6736(08)60203-9.
98. Time. A New Type of Migraine Drug Treats Pain During an Attack. https://time.com/5743585/new-migraine-drug/
99. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine attacks in adults: results from the ACHIEVE I study, a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 7;394(10214):2111-2121. doi: 10.1016/S0140-6736(19)32596-0.
100. Lipton RB, Dodick DW, Ailani J, et al. Ubrogepant for the treatment of migraine attacks in adults: results from the ACHIEVE II study, a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 7;394(10214):2122-2131. doi: 10.1016/S0140-6736(19)32597-2.
101. Croop R, Goadsby PJ, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: A phase 2/3, double-blind, randomized, placebo-controlled trial. Headache. 2020 Oct;60(9):1753-1763. doi: 10.1111/head.13962.
102. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A phase 3 double-blind, randomized, placebo-controlled trial. Lancet. 2019 Jul 13;394(10200):737-745. doi: 10.1016/S0140-6736(19)30748-0.
103. Lipton RB, Croop R, Stock D, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for the Acute Treatment of Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.
104. Croop R, Goadsby PJ, Stock DA, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: a phase 3, randomized, controlled trial. Lancet. 2019 Jul 13;394(10200):737-745. doi: 10.1016/S0140-6736(19)30748-0.
105. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: A phase 2/3, double-blind, randomized, placebo-controlled trial. Headache. 2020 Oct;60(9):1753-1763. doi: 10.1111/head.13962.
106. Time. FDA Approves a New Nasal Spray to Treat Migraines. https://time.com/6261701/nasal-spray-migraine-fda/
107. Goadsby PJ, Dodick DW, Ailani J, et al. Safety and efficacy of atogepant for the preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Nov;20(11):908-918. doi: 10.1016/S1474-4422(21)00329-8.
108. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the episodic migraine prevention: A randomized, controlled phase 3 trial (ADVANCE). Headache. 2021 Nov;61(10):1063-1073. doi: 10.1111/head.14172.
109. Dodick DW, Goadsby PJ, Ailani J, et al. Atogepant for the preventive treatment of chronic migraine: Results from the phase 3 PROGRESS study. Cephalalgia. 2023 Mar;43(3):1413-1423. doi: 10.1177/03331024221141341.
110. Ailani J, Messina SA. CGRP and its role in migraine treatment: a review. Expert Rev Neurother. 2022 Apr;22(4):307-317. doi: 10.1080/14737175.2022.2045958.
111. US FDA approves Teva’s Ajovy for migraine prevention in children. Reuters. reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-tevas-ajovy-migraine-prevention-children-2025-08-05/
112. Tepper SJ, Cleland CS, Rapoport AM, et al. Long-term safety and tolerability of erenumab in patients with episodic and chronic migraine. Cephalalgia. 2021 Mar;41(3):368-381. doi: 10.1177/0333102420959081.
113. Negro A, Curto M, Giamberardino MA, et al. CGRP monoclonal antibodies for migraine prevention in elderly patients: A narrative review of current evidence. Cephalalgia. 2022 Feb;42(2):161-171. doi: 10.1177/03331024211046427.
114. Ailani J, Raghava V, Goadsby PJ, et al. CGRP pathway monoclonal antibodies for migraine prevention in pregnancy and lactation: A systematic review. Cephalalgia. 2022 Sep;42(10):1085-1097. doi: 10.1177/03331024221087445.
115. Schwedt TJ, Goadsby PJ, Reuter U, et al. Genetic variations and the response to CGRP pathway antibodies in migraine: a systematic review. J Headache Pain. 2022 Dec 12;23(1):159. doi: 10.1186/s10194-022-01538-2.
116. Goadsby PJ, Dodick DW, Lipton RB, et al. Clinical trial perspectives on difficult-to-treat migraine. J Headache Pain. 2023 Oct 9;24(1):151. doi: 10.1186/s10194-023-01646-6.
117. Messali A, Lipton RB, Goadsby PJ, et al. Cost-effectiveness of calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine: A systematic review. Value Health. 2022 Sep;25(9):1579-1589. doi: 10.1016/j.jval.2022.04.1402.